conferenceObject
SAT0118 Calprotectin stratifies disease activity better than acute phase reactants in rheumatoid arthritis patients receiving TNF inhibitors
Registro en:
ISSN: 0959-8138
EISSN: 1756-1833
Autor
Inciarte-Mundo, J.
Hernández, M.
Ruiz-Esquide, V.
Ramírez, J.
Cuervo, A.
Amaya, J.
Pascal, M.
Yagüe, J.
Cañete, J.
Sanmarti, R.
Institución
Resumen
Background Calprotectin is a major S100 leucocyte protein, associated with disease activity in rheumatoid arthritis (RA) patients. Calprotectin is a potentially biomarker more sensitive of disease activity than conventional acute-phase reactans.